

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
16 March 2006 (16.03.2006)

PCT

(10) International Publication Number
WO 2006/029354 A1

(51) International Patent Classification⁷: **A01N 59/00**,
59/02, 25/22, C02F 1/76 // (A01N 59/00, 59:02, 59:22)

(21) International Application Number:
PCT/US2005/032239

(22) International Filing Date:
7 September 2005 (07.09.2005)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
60/607,293 7 September 2004 (07.09.2004) US

(71) Applicant (for all designated States except US): **ALBEMARLE CORPORATION** [US/US]; 451 Florida Street, Baton Rouge, LA 70801-1765 (US).

(72) Inventor; and

(75) Inventor/Applicant (for US only): **AZARNIA, Farah, D.** [US/US]; 5151 Hickory Ridge Drive, Baton Rouge, LA 70817-2051 (US).

(74) Agents: **SPIELMAN, Edgar, E., Jr.** et al.; Albemarle Corporation, 451 Florida Street, Baton Rouge, LA 70801-1765 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM,

AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.


(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

— as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii)) for the following designations AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI,

[Continued on next page]

(54) Title: CONCENTRATED AQUEOUS BROMINE SOLUTIONS AND THEIR PREPARATION



(57) Abstract: This invention provides concentrated aqueous biocidal solutions formed from bromine chloride, sodium hydroxide, and sulfamic acid. The weight ratio of bromine chloride:sodium hydroxide:sulfamic acid used in forming the concentrated solution is such that for every 10.5 to 11.5 parts by weight of bromine chloride used, 15.3 to 17.5 parts by weight of sodium hydroxide and 11.0 to 12.5 parts by weight of sulfamic acid are used, the biocidal solution containing at least about 100,000 ppm (wt/wt) of active bromine based on the total weight of the solution.

WO 2006/029354 A1



NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW, ARIPO patent (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG)

- as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii)) for the following designations AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC,

VN, YU, ZA, ZM, ZW, ARIPO patent (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG)

Published:

- with international search report
— before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

CONCENTRATED AQUEOUS BROMINE SOLUTIONS
AND THEIR PREPARATION

REFERENCE TO OTHER COMMONLY-OWNED APPLICATIONS



[0001] Reference is hereby made to the following commonly-owned applications: Application No. 09/088,300, filed 1 June 1998, now U.S. 6,068,861, issued 30 May 2000; Application No. 09/663,948, filed 18 September 2000, now U.S. 6,299,909, issued 9 October 2001; Application No. 09/442,025, filed 17 November 1999, now U.S. 6,306,441, issued 23 October 2001; Application No. 09/404,184, filed 24 September 1999, now U.S. 6,322,822, issued 27 November 2001; Application No. 09/663,788, filed 18 September 2000, now U.S. 6,348,219, issued 19 February 2002; Application No. 09/451,344, filed 30 November 1999, now U.S. 6,352,725, issued 5 March 2002; Application No. 09/456,781, filed 8 December 1999, now U.S. 6,495,169, issued 17 December 2002; Application No. 09/732,601, filed 7 December 2000, now U.S. 6,506,418, issued 14 January 2003; Application No. 09/506,911, filed 18 February 2000, now U.S. 6,511,682, issued 28 January 2003; Application No. 09/974,622, filed 9 October 2001, now U.S. 6,652,889, issued 25 November 2003; Application No. 10/269,901, filed 10 October 2002, published as U.S. 2003/0104074 on 5 June 2003; Application No. 10/282,291, filed 28 October 2002, published as U.S. 2003/0113383 on 19 June 2003; Application No. 10/282,290, filed 28 October 2002, published as U.S. 2004/0022874 on 5 February 2004; Application No. 10/703,311, filed 7 November 2003, published as U.S. 2005/0147696 on 7 July 2005. The disclosures of the above U.S. Patents and published U.S. patent applications are incorporated herein by reference as if fully set forth herein.

BACKGROUND

[0002] Bromine-based biocides have proven biocidal advantages over chlorination-dechlorination for the microbiological control of cooling waters and disinfection of waste treatment systems. The water treatment industry recognizes these advantages to include: cost-effective control at higher pH values; almost no loss in biocidal activity in the presence of ammonia; and effective control of bacteria, algae and mollusks.

[0003] A common way of introducing bromine based biocides into a water system is through the use of aqueous NaBr in conjunction with NaOCl bleach. The user feeds both materials to a common point, whereupon the NaOCl oxidizes the bromide ion to HOBr/OBr[⊖].

This activated solution is then introduced directly into the water system to be treated. The feeding of the two liquids in this fashion is necessary because the $\text{HOBr}/\text{OBr}^{\ominus}$ mixture is unstable and has to be generated on-site just prior to its introduction to the water. Furthermore, the feeding and metering of two liquids is cumbersome, especially as the system has to be designed to allow time for the activation of bromide ion to occur. Consequently, many biocide users have expressed the need for a single-feed bromine-based biocide. Elemental bromine and molecular bromine chloride have been considered to meet these demands. Both are liquids at room temperature and can be fed directly to the water system, where immediate hydrolysis occurs to yield HOBr according to the equations below.



[0004] Certain characteristics of bromine and bromine chloride -- especially their corrosiveness, high vapor pressures, and fuming tendencies -- necessitate care and skill in their handling and use. Early efforts to overcome the deficiencies of these materials comprised complexing bromine with excess bromide ion in the presence of strong acid and stabilizing the resultant solutions with ethanolamine. The resultant solutions of ethanolammonium hydrogen perbromide contained up to 38% by weight elemental bromine. See in this connection: Favstritsky, U.S. Pat. No. 4,886,915; and Favstritsky, Hein, and Squires, U.S. Pat. No. 4,966,716.

[0005] These solutions permitted introduction of bromine to a water system using a single feed. As in the case of bromine and bromine chloride, the ethanolammonium hydrogen perbromide hydrolyzed in water to release HOBr. The vapor pressures of these solutions were lower than elemental bromine and bromine chloride. Nevertheless, the solutions still possessed measurable vapor pressures, and thus tended to produce undesirable reddish-colored vapors during storage and use.

[0006] Many solid bromine derivatives such as BCDMH (1,3-bromochloro-5,5-dimethylhydantoin) are limited in the amount of material that can be dissolved in water and fed as a liquid to the water treatment system. For example, the solubility of BCDMH in water is only around 0.15%. Another limitation of such derivatives is that at neutral pH, HOBr

rapidly decomposes, eventually forming bromide ions. Thus, the ability to store and transport these aqueous solutions is greatly limited and of questionable commercial feasibility.

[0007] U.S. Pat. No. 3,558,503 to Goodenough *et al.* describes certain aqueous bromine solutions stabilized with various stabilizing agents and various uses to which such solutions can be put. The compositions described in the patent comprise an aqueous bromine solution having from about 0.01 to about 100,000 parts per million by weight of bromine values wherein the molar ratio of bromine to nitrogen present in the bromine stabilizer ranges from about 2.0 to 1 to about 0.5 to 1. The stabilizer used is biuret, succinimide, urea, a lower aliphatic mono- or disubstituted urea containing from about 2 to about 4 carbon atoms in each substituent group, sulfamic acid, or an alkyl sulfonamide of the formula RSO_3NH_2 where R is a methyl or ethyl group. The solution also contains sufficient hydroxide additive to provide a pH in the solution ranging from about 8 to about 10, the hydroxide additive being an alkaline earth hydroxide or an alkali metal hydroxide.

[0008] U.S. Pat. No. 5,683,654 to Dallmier *et al.* discusses the preparation of aqueous alkali metal or alkaline earth metal hypobromite solutions by mixing an aqueous solution of alkali or alkaline earth metal hypochlorite with a water soluble bromide ion source to form a solution of unstabilized alkali or alkaline earth metal hypochlorite. To this solution is added an aqueous solution of an alkali metal sulfamate having a temperature of at least 50°C and in an amount that provides a molar ratio of alkali metal sulfamate to alkali or alkaline earth metal hypobromite of from about 0.5 to about 6 whereby a stabilized aqueous alkali or alkaline earth metal hypobromite solution is formed. The Dallmier *et al.* patent teaches that much higher levels of available halogen for disinfection were attained by this approach as compared to the Goodenough *et al.* approach. But the Dallmier *et al.* patent acknowledges that in their process, the stabilization must occur quickly after the unstable NaOBr is formed.

[0009] New process technology for forming concentrated aqueous solutions of biocidally active bromine – and, in so doing, providing novel and eminently useful concentrated aqueous biocidal solutions formed from bromine chloride – are set forth in commonly-owned U.S. Pat. Nos. 6,068,861; 6,299,909; 6,306,441; 6,322,822; 6,348,219; 6,352,725; 6,495,169; 6,506,418; and 6,511,682, and published U.S. Pat. App. Nos. 2003/0104074; 2003/0113383; 2004/0022874; and 2005/0147696, all disclosures of which are incorporated herein by reference.

SUMMARY OF THE INVENTION

[0010] It has now been found that by careful control of the relative proportions of bromine chloride, sodium hydroxide, and sulfamic acid used in forming the concentrated aqueous biocidal solutions of the foregoing commonly-owned patents, product stability -- which is very good -- can be more consistent. Thus, this invention provides concentrated aqueous active bromine-containing biocidal solutions that possess a more consistent, superior stability.

[0011] This invention provides novel and eminently useful concentrated aqueous biocidal solutions formed from bromine chloride, sodium hydroxide, and sulfamic acid wherein the weight ratio of bromine chloride:sodium hydroxide:sulfamic acid used in forming the concentrated solutions is such that for every 10.5 to 11.5 parts by weight of bromine chloride used, 15.3 to 17.5 parts by weight of sodium hydroxide and 11.0 to 12.5 parts by weight of sulfamic acid are used. The concentration of active bromine in the concentrated aqueous biocidal solution made from these components in these relative proportions can vary as long as the finished product solution contains at least about 100,000 ppm (wt/wt) of active bromine based on the total weight of the solution. In order to achieve the more consistent stability mentioned above, the weight ratio of bromine chloride:sodium hydroxide:sulfamic acid used in forming the concentrated solutions is such that for every 10.5 to 11.5 parts by weight of bromine chloride used, 15.3 to 16.9 parts by weight of sodium hydroxide and 11.3 to 12.5 parts by weight of sulfamic acid are used. Biocidal solutions pursuant to this invention can be produced economically and straightforwardly from relatively inexpensive raw materials and, because of their effectiveness, such biocidal solutions can provide biocidal control on an economical basis. Also provided by this invention are processes for forming the concentrated aqueous active bromine containing biocidal solutions of this invention.

[0012] An embodiment of this invention is a concentrated aqueous biocidal solution formed from bromine chloride, sodium hydroxide, and sulfamic acid. The weight ratio of bromine chloride:sodium hydroxide:sulfamic acid used in forming the concentrated solution is such that for every 10.5 to 11.5 parts by weight of bromine chloride used, 15.3 to 17.5 parts by weight of sodium hydroxide and 11.0 to 12.5 parts by weight of sulfamic acid are used. The resultant concentrated aqueous biocidal solution contains at least about 100,000 ppm (wt/wt) of active bromine based on the total weight of the solution.

[0013] Another embodiment of this invention is a concentrated aqueous biocidal solution formed from water to which has been added:

- A) bromine chloride in an amount equivalent to a concentration of bromine chloride that is about 105,000 to about 115,000 ppm (wt/wt);
- B) sodium hydroxide in an amount equivalent to a concentration of sodium hydroxide that is about 153,000 to about 175,000 ppm (wt/wt); and
- C) sulfamic acid in an amount equivalent to a concentration of sulfamic acid that is about 110,000 to about 125,000 ppm (wt/wt).

The concentrations of A), B), and C) are each based on the total amount of A), B), C), and water used in forming the concentrated aqueous biocidal solution.

[0014] Still another embodiment of this invention is process of forming a concentrated aqueous biocidal solution. The process comprises mixing together in any subcombination(s) and in any sequence:

- a) bromine chloride in an amount equivalent to a concentration of bromine chloride that is about 105,000 to about 115,000 ppm (wt/wt);
- b) sodium hydroxide in an amount equivalent to a concentration of sodium hydroxide that is about 153,000 to about 175,000 ppm (wt/wt);
- c) sulfamic acid in an amount equivalent to a concentration of sulfamic acid that is about 110,000 to about 125,000 ppm (wt/wt); and
- d) water.

The concentrations of a), b), and c) are each based on the total amount of a), b), c), and water used in forming the concentrated aqueous biocidal solution.

[0015] The above and other embodiments of this invention will be still further apparent from the ensuing description and appended claims.

BRIEF DESCRIPTION OF THE DRAWINGS

[0016] Fig. 1 is a graph comparing the thermal stability at 104°F of concentrated aqueous biocidal solutions of the invention with a biocidal solution in which the ratios of weight ratio of bromine chloride:sodium hydroxide:sulfamic acid used in forming the biocidal solutions is outside that of the present invention.

[0017] Fig. 2 is a graph comparing the thermal stability at 130°F of concentrated aqueous biocidal solutions of the invention with a biocidal solution in which the ratios of weight ratio of bromine chloride:sodium hydroxide:sulfamic acid used in forming the biocidal solutions is outside that of the present invention.

FURTHER DETAILED DESCRIPTION OF THE INVENTION

[0018] Any method of the foregoing commonly-owned patents can be used in producing these new concentrated aqueous biocidal solutions, provided the bromine chloride, sodium hydroxide, and sulfamic acid are used in the relative proportions given in the preceding summary of the invention, and the quantities relative to the amount of water used in preparing the concentrated solution are such that the finished product solution contains at least 100,000 ppm (wt/wt) of active bromine on a weight basis, based on the total weight of the solution. These finished product solutions of this invention may contain as much as, say, about 145,000 to about 160,000 ppm (wt/wt) of active bromine based on the total weight of the solution. Indeed, finished product solutions having as much as about 180,000 ppm (wt/wt) or more of active bromine (based on the total weight of the solution) can be formed and provided pursuant to this invention.

[0019] Unless specifically stated otherwise herein, ppm means parts per million (wt/wt), based on the total weight of the solution. In this connection, there is a relationship between parts per million (wt/wt) and weight percent. For example, 100,000 ppm (wt/wt) is usually considered to be equivalent to 10 wt%.

[0020] Bromine chloride is usually formed from bromine and chlorine. In each of the compositions of the invention, the bromine chloride used is believed to be an equilibrium mixture. Thus, if the bromine and chlorine are mixed in molar proportions other than 1:1, the bromine chloride is believed to also contain the halogen used in excess. Preferably, equimolar amounts of bromine and chlorine or a slight excess of bromine is used in forming the bromine chloride used in the practice of this invention.

[0021] In order to employ bromine chloride most efficiently when forming the concentrated aqueous biocidal solutions of the invention, the bromine chloride is fed in the form of a liquid under pressure and typically under such conditions that the equilibrium mixture actually contains about 85 mole percent of bromine chloride, about 7.5 mole percent of bromine, and

about 7.5 mole percent of chlorine. Thus, the proportions given herein relative to bromine chloride are based on use of such a liquid equilibrium mixture. In this same connection, the proportions given herein for sulfamic acid and for sodium hydroxide are for materials as if they are in the solid state and of commercial purity.

[0022] Pursuant to this invention, the weight ratio of bromine chloride:sodium hydroxide:sulfamic acid is calculated based on the combined weight of these three components only. Other substances (such as water) used to form the solution are excluded from this ratio calculation. For example, even though the sodium hydroxide may be fed as an aqueous solution, only the weight of the sodium hydroxide itself is used in the calculation. When calculating the weight ratio of bromine chloride:sodium hydroxide:sulfamic acid, the combined weight of the bromine and chlorine used in forming the bromine chloride is used for calculating the ratio, even though it is understood that not all of the bromine chloride may be in the form of bromine chloride, as discussed above.

[0023] The term “active bromine” of course refers to all bromine-containing species that are capable of biocidal activity. It is generally accepted in the art that all of the bromine in the +1 oxidation state is biocidally active and is thus included in the term “active bromine.” As is well known in the art, bromine chloride has bromine in the +1 oxidation state. Thus, bromine chloride – as well as other such species, to the extent they are present – constitutes the active bromine content of the solutions of this invention. See, for example, U.S. 4,382,799 and U.S. 5,679,239. A well-established method in the art for determining the amount of active bromine in a solution is starch-iodine titration, which determines all of the active bromine in a sample regardless of what species may constitute the active bromine. The usefulness and accuracy of the classical starch-iodine method for quantitative determination of bromine and many other oxidizing agents has long been known, as witness Chapter XIV of Willard-Furman, *Elementary Quantitative Analysis*, Third Edition, D. Van Nostrand Company, Inc., New York, Copyright 1933, 1935, 1940.

[0024] A typical starch-iodine titration to determine active bromine is carried out as follows. A magnetic stirrer and 50 milliliters (mL) of glacial acetic acid are placed in an iodine flask. The sample (usually about 0.2-0.5g) for which the active bromine is to be determined is weighed and added to the flask containing the acetic acid. Water (50 mL) and aqueous potassium iodide (15% (wt/wt); 25 mL) are then added to the flask. The flask is stoppered

using a water seal. The solution is then stirred for fifteen minutes, after which the flask is unstoppered and the stopper and seal area are rinsed into the flask with water. An automatic buret (Metrohm Limited) is filled with 0.1 normal (N) sodium thiosulfate. The solution in the iodine flask is titrated with the 0.1 N sodium thiosulfate; when a faint yellow color is observed, one mL of a 1 wt% starch solution in water is added, changing the color of the solution in the flask from faint yellow to blue. Titration with sodium thiosulfate continues until the blue color disappears. The amount of active bromine is calculated using the weight of the sample and the volume of sodium thiosulfate solution titrated. Thus, the amount of active bromine in a composition of this invention, regardless of actual chemical form, can be quantitatively determined.

[0025] In one embodiment, the concentrated aqueous biocidal solutions of this invention are formed from bromine chloride, sodium hydroxide, and sulfamic acid. Water is also used in forming the concentrated aqueous biocidal solution. The amounts of bromine chloride, sodium hydroxide, and sulfamic acid used to form the concentrated solution are in a weight ratio of bromine chloride:sodium hydroxide:sulfamic acid such that for every 10.5 to 11.5 parts by weight of bromine chloride used, 15.3 to 17.5 parts by weight of sodium hydroxide and 11.0 to 12.5 parts by weight of sulfamic acid are used. The concentrated aqueous biocidal solution formed from bromine chloride, sodium hydroxide, and sulfamic acid in the given ratio has a concentration of bromine chloride that is high enough that the concentrated aqueous biocidal solution contains at least about 100,000 ppm (wt/wt) of active bromine based on the total weight of the solution. Preferably, the concentrated aqueous biocidal solution is such that for every 10.5 to 11.5 parts by weight of bromine chloride used, 15.3 to 16.9 parts by weight of sodium hydroxide and 11.3 to 12.5 parts by weight of sulfamic acid are used to form the concentrated aqueous biocidal solution; in these preferred ranges, the more consistent stability described above can be achieved.

[0026] In a more preferred embodiment, the concentrated aqueous biocidal solution of this invention is such that for every 10.8 to 11.2 parts by weight of bromine chloride used, 16.1 to 16.8 parts by weight of sodium hydroxide and 11.6 to 11.9 parts by weight of sulfamic acid are used to form the concentrated aqueous biocidal solution. Nominally, such proportions are about 11.0 parts by weight of bromine chloride, about 16.1 parts by weight of sodium hydroxide, and about 11.9 parts by weight of sulfamic acid. These more preferred proportions

also allow the achievement of more consistent stability for the formed concentrated aqueous biocidal solutions.

[0027] In another embodiment, a concentrated aqueous biocidal solution of this invention is formed from water to which has been added:

- A) bromine chloride in an amount equivalent to a concentration of bromine chloride that is about 105,000 to about 115,000 ppm (wt/wt);
- B) sodium hydroxide in an amount equivalent to a concentration of sodium hydroxide that is about 153,000 to about 175,000 ppm (wt/wt); and
- C) sulfamic acid in an amount equivalent to a concentration of sulfamic acid that is about 110,000 to about 125,000 ppm (wt/wt).

The concentrations of A), B), and C) are each based on the total amount of A), B), C), and water used in forming the concentrated aqueous biocidal solution. The phrase "in an amount equivalent to a concentration of" means that the amounts of bromine chloride, sodium hydroxide, and sulfamic acid added to form the concentrated aqueous biocidal solution are such that the amount added would give a concentration in the recited range. Preferably, in order to achieve the more consistent stability referred to above, the sodium hydroxide is added in an amount to make a concentration in the solution of about 153,000 to about 169,000 ppm (wt/wt); in the preferred ranges, the more consistent stability described above can be achieved.

[0028] In more preferred embodiments, the concentrated aqueous biocidal solutions of this invention are formed from water to which has been added:

- A) about 108,000 to about 112,000 ppm (wt/wt) of bromine chloride;
- B) about 161,000 to about 168,000 ppm (wt/wt) of sodium hydroxide; and
- C) about 116,000 to about 119,000 ppm (wt/wt) of sulfamic acid.

These more preferred proportions also allow the achievement of more consistent stability for the formed concentrated aqueous biocidal solutions. Such concentrations provide biocidal solutions which nominally contain about 110,000 ppm of bromine chloride, about 161,000 ppm of sodium hydroxide, and about 119,000 ppm of sulfamic acid.

[0029] In any of the above embodiments, at least a portion of the sodium hydroxide can be used in the form of an aqueous solution when forming the concentrated aqueous biocidal solution.

[0030] In another embodiment, this invention provides a process of forming a concentrated aqueous biocidal solution. The process comprises mixing together in any subcombination(s) and in any sequence:

- a) bromine chloride in an amount equivalent to a concentration of bromine chloride that is about 105,000 to about 115,000 ppm (wt/wt);
- b) sodium hydroxide in an amount equivalent to a concentration of sodium hydroxide that is about 153,000 to about 175,000 ppm (wt/wt);
- c) sulfamic acid in an amount equivalent to a concentration of sulfamic acid that is about 110,000 to about 125,000 ppm (wt/wt); and
- d) water.

The concentrations of a), b), and c) are each based on the total amount of a), b), c), and water used in forming the concentrated aqueous biocidal solution. The phrase "in an amount equivalent to a concentration of" means that the amounts of bromine chloride, sodium hydroxide, and sulfamic acid mixed together to form the concentrated aqueous biocidal solution are such that the amount mixed would give a concentration in the recited range. Preferably, the concentrated aqueous biocidal solution formed by mixing together bromine chloride, sodium hydroxide, sulfamic acid, and water contains at least about 100,000 ppm (wt/wt) of active bromine. More preferably, the concentrated aqueous biocidal solution contains about 145,000 to about 160,000 ppm (wt/wt) of active bromine.

[0031] In a preferred embodiment, the process of forming a concentrated aqueous biocidal solution comprises mixing together in any subcombination(s) and in any sequence:

- a) bromine chloride in an amount equivalent to a concentration of bromine chloride that is about 105,000 to about 115,000 ppm (wt/wt);
- b) sodium hydroxide in an amount equivalent to a concentration of sodium hydroxide that is about 153,000 to about 169,000 ppm (wt/wt);
- c) sulfamic acid in an amount equivalent to a concentration of sulfamic acid that is about 113,000 to about 125,000 ppm (wt/wt); and
- d) water.

In these preferred ranges, the more consistent stability described above can be achieved.

[0032] In a more preferred embodiment, the process of forming a concentrated aqueous biocidal solution comprises mixing together in any subcombination(s) and in any sequence:

- a) bromine chloride in an amount equivalent to a concentration of bromine chloride that is about 108,000 to about 112,000 ppm (wt/wt);
- b) sodium hydroxide in an amount equivalent to a concentration of sodium hydroxide that is about 161,000 to about 168,000 ppm (wt/wt);
- c) sulfamic acid in an amount equivalent to a concentration of sulfamic acid that is about 116,000 to about 119,000 ppm (wt/wt); and
- d) water.

The more preferred proportions also allow the achievement of more consistent stability for the formed concentrated aqueous biocidal solutions. Such concentrations provide biocidal solutions in which a) is nominally in an amount equivalent to a concentration of bromine chloride that is nominally about 110,000 ppm (wt/wt), b) is nominally in an amount equivalent to a concentration of sodium hydroxide of about 161,000 ppm (wt/wt), and c) is nominally in an amount equivalent to a concentration of sulfamic acid of about 119,000 ppm (wt/wt).

[0033] In a preferred embodiment, (i) the sodium hydroxide is any alkali metal hydroxide; or (ii) the sulfamic acid is an alkali metal sulfamate; or (iii) the sodium hydroxide is any alkali metal hydroxide and the sulfamic acid is an alkali metal sulfamate. More preferably, the alkali metal hydroxide is sodium hydroxide, potassium hydroxide, or both sodium hydroxide and potassium hydroxide. Even more preferred are sodium sulfamate, potassium sulfamate, or both sodium sulfamate and potassium sulfamate as the alkali metal sulfamate. A highly preferred alkali metal sulfamate is sodium sulfamate.

[0034] In all of the above embodiments, at least a portion of the water of solution may be introduced with the sodium hydroxide and/or with the sulfamic acid, and/or via a separate feed. The amounts in ppm (wt/wt) in all of the above embodiments are based on the total weight of the formed biocidal solution.

[0035] While sodium hydroxide and sulfamic acid are used preferably, in the practice of this invention equivalent amounts of other alkali metal hydroxides and equivalent amounts of alkali metal salts of sulfamic acid can be used in all of the embodiments of this invention. Mixtures of two or more alkali metal hydroxides and/or mixtures of two or more alkali metal sulfamates can be used. Mixtures of one or more alkali metal sulfamate and sulfamic acid can also be used. For simplicity, it is preferred to use one alkali metal hydroxide and it is also preferred to use sulfamic acid alone, as one alkali metal sulfamate, or as a mixture of sulfamic

acid and one alkali metal sulfamate. Preferably, the alkali metal hydroxide used in the practice of this invention is sodium hydroxide and/or potassium hydroxide; more preferably, the alkali metal hydroxide is sodium hydroxide. Preferred alkali metal sulfamates are sodium sulfamate and potassium sulfamate, with sodium sulfamate being more preferred.

[0036] Optional ingredients may be included in the concentrated aqueous biocidal solutions of the invention. These optional ingredients include fragrances, stabilizers, corrosion inhibitors, dyes, other biocidal agents, surfactants, effervescent, diluents, builders, chelating agents, dispersants, and the like. Such ancillary materials should of course be compatible with the biocidal solution and not interfere in any material way with the performance characteristics of the concentrated aqueous biocidal solution.

[0037] It is to be understood that some or all of the sulfamic acid used in forming the concentrated aqueous product solutions of this invention can first be neutralized by some of the sodium hydroxide to form sodium sulfamate, which is then used along with the remainder of the sodium hydroxide in forming such concentrated aqueous biocidal solutions. In other words, the aqueous solution of alkali metal salt of sulfamic acid can be preformed by mixing together in water, (I) sulfamic acid and/or an alkali metal salt of sulfamic acid, and (II) alkali metal base in proportions such that an aqueous solution of alkali metal salt of sulfamic acid is formed, preferably having a pH of at least 12. When sulfamic acid itself is used as the starting material for forming an alkali metal sulfamate, it is used initially as a slurry in water with which the alkali metal base is mixed.

[0038] When introducing bromine chloride into an aqueous solution of alkali metal salt of sulfamic acid (preferably formed from sulfamic acid and sodium hydroxide), it is desirable to maintain the desired pH of the solution at 7 or above by also introducing into the solution (continuously or intermittently, as desired) additional alkali metal base, such as by a co-feed of an aqueous solution of alkali metal base (preferably an aqueous solution of sodium hydroxide) during the feeding of the bromine chloride. When the concentrated aqueous biocidal solution is to be stored (*e.g.*, in drums), and especially when being stored for a prolonged length of time, it is desirable to have the pH of such solution at about 10 or above. The concentrated aqueous biocidal solutions of this invention preferably have a pH of at least about 12; more preferred is a pH in the range of about 12.5 to about 14. Still more preferably, the pH of the concentrated aqueous biocidal solutions is in the range of about 13 to about 14.

[0039] A general, non-limiting procedure for preparing the compositions of this invention using sulfamic acid involves, as a first step, forming a slurry of sulfamic acid in water. Typically the pH of this slurry is below 1 pH unit. Sodium hydroxide (at, *e.g.*, 25 wt% or 50 wt% concentration) is then added until the solid is completely dissolved. Additional sodium hydroxide (at, *e.g.*, 25 wt% or 50 wt% concentration) is added until the desired pH is reached. Bromine chloride is then added at a rate to allow the bromine chloride to dissolve and react with the sulfamic acid without forming a pool of halogen on the bottom of the reactor. On a laboratory scale, a convenient rate of addition is approximately two drops per second. Sodium hydroxide (*e.g.*, 25 wt% or 50 wt%) is co-fed to the reactor to maintain the desired pH (*e.g.*, in the range of 7 to about 13.5, and it may be possible to operate even at a pH in the range of 13.5 to 14). It has been found that stable solutions containing as much as 16 wt% active bromine as bromine chloride can be prepared by the process of this invention.

[0040] At present, a preferred way of conducting the process of this invention on a larger scale involves charging to a reactor water, aqueous alkali metal hydroxide solution (preferably aqueous sodium hydroxide solution), sulfamic acid, and then bromine chloride. Preferred proportions of the components are 12.7 parts by weight of water, 64.4 parts by weight of a 25 wt% aqueous sodium hydroxide solution, 11.9 parts by weight of sulfamic acid, and 11 parts by weight of bromine chloride, for a total of 100 parts by weight. Preferably these components are charged in the order named. However, as long as the bromine chloride is charged last, the order of addition of the other three components can be varied. The bromine chloride used preferably contains in the range of 68.9 to 73.1 wt% bromine. However, pure bromine chloride or other combinations of bromine chloride and bromine can be used to make effective product, if desired. The temperature of the mixture during the addition of the bromine chloride is preferably not allowed to exceed 50°C, although the temperature can be allowed to go above 50°C for short periods of time without detrimental effects. Prolonged exposure to elevated temperatures tends to cause degradation of the product, and thus should be avoided. The bromine chloride concentration in the resultant product biocidal solution as formed in this manner (and in whatever chemical form or forms the active bromine chloride exists in such solution), is in the range of about 10.5 wt% to about 11.5 wt% (*i.e.*, between about 105,000 and about 115,000 ppm (wt/wt)), and preferably is in the range of about 10.8 wt% to about 11.2 wt% (*i.e.*, between about 108,000 to about 112,000 ppm (wt/wt)).

Determination of the active bromine concentration can, of course, be readily accomplished by starch-iodine titration. When operating as described in this paragraph, the final pH of the product solution is in the range of about 12.4 to about 13.7.

[0041] Another preferred way of operating on a larger scale the process described in the immediately preceding paragraph is in a semi-continuous or semi-batch mode. This involves forming the alkali metal sulfamate solution, preferably a sodium sulfamate solution (using caustic, water, and sulfamic acid), and feeding in the bromine chloride to a suitable vessel (reactor, tank, *etc.*) containing the sulfamate solution. The BrCl may go straight into the vessel of the aqueous sodium sulfamate or into a pumparound loop on the vessel. The BrCl may be made up ahead of time, or can be made by continuously mixing the bromine and chlorine together in a pipe, with or without a mixing element, and then injecting it straight into the aqueous sodium sulfamate without isolating the BrCl. The advantage of continuously making the BrCl is that this avoids having a separate BrCl reactor or storage tank and the need for keeping a large quantity of this material in storage on plant facilities.

[0042] The following Examples are presented for purposes of illustration and not limitation. These Examples set forth preferred procedures for preparing a biocidal concentrated aqueous biocidal solution of this invention.

EXAMPLE 1

[0043] The total quantities of the components used in forming a preferred composition of this invention are as follows: 7.81 g bromine, 3.19 g chlorine (to form bromine chloride), 32.2 g 50 wt% aqueous sodium hydroxide solution, 11.9 g sulfamic acid, and 44.9 g water. The procedure used involves charging water to the reactor, followed by separately cofeeding sulfamic acid and aqueous 50 wt% sodium hydroxide solution to the reactor while maintaining the temperature at about 70 to about 80°F (about 21 to about 27°C) and the pH at about 9 to about 12. Next, bromine chloride and aqueous 50% sodium hydroxide solution are separately co-fed into the reactor while maintaining the temperature below about 80°F (about 26°C or less) and the pH in the range of about 8 to about 12. The mixture is then held under these conditions for about 15 minutes. Then, the remainder of the aqueous 50 wt% sodium hydroxide solution is added. Typically, the pH of the resultant product solution will be greater than about 12.

EXAMPLE 2

[0044] A 500 mL round-bottom flask was charged with water (129.1 g) and sulfamic acid (112.3 g). The resultant slurry was stirred and then aqueous sodium hydroxide solution (50 wt%, 303.7 g) was slowly introduced. The flask contents were kept below 30°C during the addition. Chlorine (31.2 g) was added to 75.9 g of bromine (to form bromine chloride), and then added to the flask. The flask contents again were kept below 30°C during the addition. At the end of the bromine chloride addition, a slightly hazy orange solution was obtained. The solution had a BrCl:NaOH:sulfamic acid ratio of 11.0:15.6:11.5. The activity of the product solution was 15.9 wt% as bromine chloride, as determined by starch-iodine titration, corresponding to 22.0 wt% active bromine on a Br₂ basis.

EXAMPLE 3

[0045] A commercial-size glass-lined reactor was charged with water. Sulfamic acid and sodium hydroxide (50 wt%) were co-fed while maintaining the pH between 9 and 12. Bromine chloride and aqueous sodium hydroxide (50 wt%) were then co-fed under essentially the same conditions, followed by a final charge of aqueous sodium hydroxide (50 wt%) to make the pH of the solution greater than 12. The temperature during these operations was maintained at 80°F (~27°C) or less. The amounts of reagents used were such that 11.2 parts BrCl, 16.1 parts sodium hydroxide (100% solids basis), and 11.6 parts sulfamic acid had been added to the reactor. The activity of the product was 11.0 wt% as BrCl as determined by the KI/thiosulfate method. This corresponds to 15.2 wt% active bromine on a Br₂ basis. The pH of the product solution was 13.4.

EXAMPLE 4

[0046] A solution was prepared as described in Example 3. The amounts of reagents used were such that 11.2 parts BrCl, 16.1 parts sodium hydroxide (100% solids basis), and 11.6 parts sulfamic acid had been added to the reactor. The activity of the product was 11.1 wt% as BrCl as determined by the KI/thiosulfate method, which corresponds to 15.4 wt% active bromine on a Br₂ basis. The pH of the product solution was 13.5.

EXAMPLE 5

[0047] Solutions of the invention (Runs 1-3) were prepared as described in Examples 3 and 4. For comparison, a solution having ~11.0 parts BrCl, ~14.75 parts sodium hydroxide, and ~13.0 parts sulfamic acid were also made (Run A; preparation of this solution was otherwise similar to that in Examples 3 and 4). To test their thermal stability, samples of these solutions were exposed to room temperature, 104°F (40°C), or 130°F (54°C) for three to six months. The results of these studies are summarized in Tables 1-3; the activities in Tables 1-3 are in weight percent, as BrCl. The activities of the solutions were determined by the KI/thiosulfate method. The column labeled "Retained" shows how much of the original activity remains after the elapsed time.

TABLE 1 (Room temperature)

| Solution | Run 1 | | Run 2 | | Run 3 | | Run A | |
|----------|----------|----------|----------|----------|----------|----------|----------|----------|
| | wt% BrCl | Retained | wt% BrCl | Retained | wt% BrCl | Retained | wt% BrCl | Retained |
| Initial | 10.6 | | 11.0 | | 11.21 | 100% | 10.57 | |
| 12 weeks | 10.63 | 100% | 11.02 | 100% | 11.20* | 99.9% | 10.6 | 100% |
| 24 weeks | 10.62 | 100% | 10.98 | 99.8% | 10.68 | 98.5% | 10.59 | 100% |

*This solution was measured after 13 weeks.

TABLE 2 (104°F)

| Solution | Run 1 | | Run 2 | | Run 3 | | Run A | |
|----------|----------|----------|----------|----------|----------|----------|----------|----------|
| | wt% BrCl | Retained | wt% BrCl | Retained | wt% BrCl | Retained | wt% BrCl | Retained |
| Initial | 10.6 | | 11.0 | | 11.21 | | 10.57 | |
| 6 weeks | 10.37 | 97.8% | 10.72 | 97.5% | 10.72 | 95.6% | 10.06 | 95.2% |
| 12 weeks | 9.99 | 94.3% | 10.28 | 93.5% | 10.38* | 92.6% | 9.65 | 91.3% |
| 16 weeks | 9.87 | 93.1% | 10.09 | 91.7% | 10.07 | 89.8% | 9.28 | 87.8% |
| 24 weeks | 9.40 | 88.7% | 9.63 | 87.6% | 9.55 | 85.2% | 8.62 | 81.7% |

*This solution was measured after 13 weeks.

TABLE 3 (130°F)

| Solution | Run 1 | | Run 2 | | Run 3 | | Run A | |
|----------|----------|----------|----------|----------|----------|----------|----------|----------|
| | wt% BrCl | Retained | wt% BrCl | Retained | wt% BrCl | Retained | wt% BrCl | Retained |
| Initial | 10.6 | | 11.0 | | 11.21 | | 10.57 | |
| 1 week | 10.04 | 94.7% | 10.24 | 93.1% | 10.56 | 94.2% | 9.54 | 90.3% |
| 3 weeks | 9.14 | 86.2% | 9.28 | 84.4% | 9.25 | 82.5% | 8.07 | 76.4% |
| 6 weeks | 8.09 | 76.3% | 8.04 | 73.1% | 7.99 | 71.3% | 6.31 | 59.7% |
| 10 weeks | 6.90 | 65.1% | 6.75 | 61.4% | 6.71 | 59.9% | 4.53 | 42.9% |
| 12 weeks | 6.45 | 60.9% | 6.33 | 57.5% | 6.18 | 55.1% | 3.91 | 37.0% |

[0048] Tables 1-3 show that although the comparative solution of Run A are stable, the solutions of the present invention (Runs 1-3) exhibit a more consistent stability over time, especially upon prolonged exposure to increased temperatures. The data regarding the percent of activity retained in Table 2 is presented graphically in Figure 1, and the data regarding the percent of activity retained in Table 3 is presented graphically in Figure 2. The Figures show that for both 104°F and 130°F, while there is decay in the amount of activity in all of the solutions tested, the solutions of the invention (labeled 1, 2, and 3 in the Figures) retained a greater amount of activity over time as compared to that of the comparative solution (labeled A in the Figures).

[0049] Even though the claims hereinafter may refer to substances, components and/or ingredients in the present tense (“comprises”, “is”, *etc.*), the reference is to the substance, component or ingredient as it existed at the time just before it was first contacted, blended or mixed with one or more other substances, components and/or ingredients, or if formed in solution, as it would exist if not formed in solution, all in accordance with the present disclosure. It matters not that a substance, component or ingredient may have lost its original identity through a chemical reaction or transformation during the course of such contacting, blending, mixing, or *in situ* formation, if conducted in accordance with this disclosure.

[0050] Each and every patent or publication referred to in any portion of this specification is incorporated into this disclosure by reference, as if fully set forth herein.

[0051] This invention is susceptible to considerable variation in its practice. Therefore the foregoing description is not intended to limit, and should not be construed as limiting, the invention to the particular exemplifications presented hereinabove. Rather, what is intended to be covered is as set forth in the ensuing claims and the equivalents thereof permitted as a matter of law.

CLAIMS:

1. A concentrated aqueous biocidal solution formed from bromine chloride, sodium hydroxide, and sulfamic acid wherein the weight ratio of bromine chloride:sodium hydroxide:sulfamic acid used in forming the concentrated solution is such that for every 10.5 to 11.5 parts by weight of bromine chloride used, 15.3 to 17.5 parts by weight of sodium hydroxide and 11.0 to 12.5 parts by weight of sulfamic acid are used, said biocidal solution containing at least about 100,000 ppm (wt/wt) of active bromine based on the total weight of said solution.
2. A solution as in Claim 1 wherein said weight ratio is such that for every 10.5 to 11.5 parts by weight of bromine chloride used, 15.3 to 16.9 parts by weight of sodium hydroxide and 11.3 to 12.5 parts by weight of sulfamic acid are used.
3. A solution as in Claim 1 wherein said weight ratio is such that for every 10.8 to 11.2 parts by weight of bromine chloride used, 16.1 to 16.8 parts by weight of sodium hydroxide and 11.6 to 11.9 parts by weight of sulfamic acid are used.
4. A solution as in Claim 3 wherein said weight ratio is such that for every 11.0 parts by weight of bromine chloride, about 16.1 parts by weight of sodium hydroxide and about 11.9 parts by weight of sulfamic acid are used.
5. A solution as in Claim 4 wherein said biocidal solution has a pH of at least about 12.
6. A solution as in any of Claims 1-5 wherein said biocidal solution contains in the range of about 145,000 to about 160,000 ppm (wt/wt) of active bromine.
7. A solution as in any of Claims 1-5 wherein at least a portion of the sodium hydroxide is used in the form of an aqueous solution.
8. A solution as in any of Claims 1-5 wherein said biocidal solution has a pH of at least about 10.
9. A concentrated aqueous biocidal solution formed from water to which has been added:
 - A) bromine chloride in an amount equivalent to a concentration of bromine chloride that is about 105,000 to about 115,000 ppm (wt/wt);
 - B) sodium hydroxide in an amount equivalent to a concentration of sodium hydroxide

that is about 153,000 to about 175,000 ppm (wt/wt); and

- C) sulfamic acid in an amount equivalent to a concentration of sulfamic acid that is about 110,000 to about 125,000 ppm (wt/wt),

wherein the concentrations of A), B), and C) are each based on the total amount of A), B), C), and water used.

10. A solution as in Claim 9 formed from water to which has been added:

- A) bromine chloride in an amount equivalent to a concentration of bromine chloride that is about 105,000 to about 115,000 ppm (wt/wt);
- B) sodium hydroxide in an amount equivalent to a concentration of sodium hydroxide that is about 153,000 to about 169,000 ppm (wt/wt); and
- C) sulfamic acid in an amount equivalent to a concentration of sulfamic acid that is about 113,000 to about 125,000 ppm (wt/wt),

wherein the concentrations of A), B), and C) are each based on the total amount of A), B), C), and water used.

11. A solution as in Claim 9 formed from water to which has been added:

- A) bromine chloride in an amount equivalent to a concentration of bromine chloride that is about 108,000 to about 112,000 ppm (wt/wt);
- B) sodium hydroxide in an amount equivalent to a concentration of sodium hydroxide that is about 161,000 to about 168,000 ppm (wt/wt); and
- C) sulfamic acid in an amount equivalent to a concentration of sulfamic acid that is about 116,000 to about 119,000 ppm (wt/wt),

wherein the concentrations of A), B), and C) are each based on the total amount of A), B), C), and water used.

12. A solution as in Claim 11 formed from water to which has been added:

- A) bromine chloride in an amount equivalent to a concentration of bromine chloride that is nominally about 110,000 ppm (wt/wt);
- B) sodium hydroxide in an amount equivalent to a concentration of sodium hydroxide that is nominally about 161,000 ppm (wt/wt); and
- C) sulfamic acid in an amount equivalent to a concentration of sulfamic acid that is nominally about 119,000 ppm (wt/wt),

wherein the concentrations of A), B), and C) are each based on the total amount of A), B), C), and water used.

13. A solution as in Claim 12 wherein said biocidal solution has a pH of at least about 12.

14. A solution as in any of Claims 9-12 wherein said biocidal solution has a pH of at least about 10.

15. A solution as in any of Claims 9-12 wherein said biocidal solution has at least about 100,000 ppm (wt/wt) of active bromine based on the total weight of said solution.

16. A solution as in any of Claims 9-12 wherein said biocidal solution contains in the range of about 145,000 to about 160,000 ppm (wt/wt) of active bromine based on the total weight of said solution.

17. A solution as in Claim 1 or 9 wherein: (i) an equivalent amount of at least one other alkali metal hydroxide is used in place of at least a portion of the sodium hydroxide; or (ii) an equivalent amount of an alkali metal sulfamate is used in place of at least a portion of the sulfamic acid; or (iii) an equivalent amount of at least one other alkali metal hydroxide is used in place of at least a portion of the sodium hydroxide and an equivalent amount of an alkali metal sulfamate is used in place of at least a portion of the sulfamic acid.

18. A solution as in Claim 17 wherein the alkali metal hydroxide is sodium hydroxide, potassium hydroxide, or both sodium hydroxide and potassium hydroxide.

19. A solution as in Claim 17 wherein the alkali metal sulfamate is sodium sulfamate, potassium sulfamate, or both sodium sulfamate and potassium sulfamate.

20. A process of forming a concentrated aqueous biocidal solution which comprises mixing together in any subcombination(s) and in any sequence:

- a) bromine chloride in an amount equivalent to a concentration of bromine chloride that is about 105,000 to about 115,000 ppm (wt/wt);
- b) sodium hydroxide in an amount equivalent to a concentration of sodium hydroxide that is about 153,000 to about 175,000 ppm (wt/wt);
- c) sulfamic acid in an amount equivalent to a concentration of sulfamic acid that is about 110,000 to about 125,000 ppm (wt/wt); and
- d) water,

wherein the concentrations of a), b), and c) are each based on the total amount of a), b), c), and water used.

21. A process as in Claim 20 wherein the amount in a) is an amount equivalent to a concentration of bromine chloride that is about 105,000 to about 115,000 ppm (wt/wt), wherein the amount in b) is an amount equivalent to a concentration of sodium hydroxide that is about 153,000 to about 169,000 ppm (wt/wt), and wherein the amount in c) is an amount equivalent to a concentration of sulfamic acid that is about 113,000 to about 125,000 ppm (wt/wt).

22. A process as in Claim 20 wherein the amount in a) is an amount equivalent to a concentration of bromine chloride that is about 108,000 to about 112,000 ppm (wt/wt), wherein the amount in b) is an amount equivalent to a concentration of sodium hydroxide that is about 161,000 to about 168,000 ppm (wt/wt), and wherein the amount in c) is an amount equivalent to a concentration of sulfamic acid that is about 116,000 to about 119,000 ppm (wt/wt).

23. A process as in Claim 22 wherein the amount in a) is an amount equivalent to a concentration of bromine chloride that is nominally about 110,000 ppm (wt/wt), wherein the amount in b) is an amount equivalent to a concentration of sodium hydroxide that is nominally about 161,000 ppm (wt/wt), and wherein the amount in c) is an amount equivalent to a concentration of sulfamic acid that is nominally about 119,000 ppm (wt/wt).

24. A process as in any of Claims 20-23 wherein said mixing together forms a biocidal solution containing at least about 100,000 ppm (wt/wt) of active bromine based on the total weight of said solution.

25. A solution as in any of Claims 20-23 wherein said mixing together forms a biocidal solution containing in the range of about 145,000 to about 160,000 ppm (wt/wt) of active bromine based on the total weight of said solution.

26. A process as in Claim 20 wherein: (i) the sodium hydroxide is any alkali metal hydroxide; or (ii) the sulfamic acid is an alkali metal sulfamate; or (iii) the sodium hydroxide is any alkali metal hydroxide and the sulfamic acid is an alkali metal sulfamate.

27. A process as in Claim 26 wherein the alkali metal hydroxide is sodium hydroxide, potassium hydroxide, or both sodium hydroxide and potassium hydroxide.

28. A process as in Claim 26 wherein the alkali metal sulfamate is sodium sulfamate, potassium sulfamate, or both sodium sulfamate and potassium sulfamate.

Fig. 1
Thermal Stability at 104° F





Fig. 2
Thermal Stability at 130° F



INTERNATIONAL SEARCH REPORT

ational Application No
/US2005/032239

A. CLASSIFICATION OF SUBJECT MATTER

A01N59/00 A01N59/02 A01N25/22 C02F1/76
//(A01N59/00,59:02,25:22)

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

A01N C02F

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, WPI Data, CHEM ABS Data

C. DOCUMENTS CONSIDERED TO BE RELEVANT

| Category ° | Citation of document, with indication, where appropriate, of the relevant passages | Relevant to claim No. |
|------------|--|-----------------------|
| A | WO 99/62339 A (ALBEMARLE CORPORATION) 9 December 1999 (1999-12-09) cited in the application abstract example 7; table 2 | 1-28 |
| A | WO 01/20996 A (ALBEMARLE CORPORATION) 29 March 2001 (2001-03-29) cited in the application abstract examples 3,4; table 2 | 1-28 |
| A | WO 2004/039159 A (ALBEMARLE CORPORATION) 13 May 2004 (2004-05-13) cited in the application abstract page 4, paragraph 4 | 1-28 |

☐ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

° Special categories of cited documents :

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier document but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"&" document member of the same patent family

Date of the actual completion of the international search

17 January 2006

Date of mailing of the international search report

24/01/2006

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

Molina de Alba, J

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No
/US2005/032239

| Patent document cited in search report | | Publication date | Patent family member(s) | Publication date |
|---|---|---------------------|----------------------------|---------------------|
| WO 9962339 | A | 09-12-1999 | AU 757890 B2 | 13-03-2003 |
| | | | AU 3882099 A | 20-12-1999 |
| | | | CA 2333059 A1 | 09-12-1999 |
| | | | DE 69906066 D1 | 24-04-2003 |
| | | | DE 69906066 T2 | 24-12-2003 |
| | | | EP 1083794 A1 | 21-03-2001 |
| | | | ES 2195570 T3 | 01-12-2003 |
| | | | JP 2002516827 T | 11-06-2002 |
| | | | US 6068861 A | 30-05-2000 |
| | | | US 6322822 B1 | 27-11-2001 |
| | | | US 6306441 B1 | 23-10-2001 |
| | | | US 6495169 B1 | 17-12-2002 |
| WO 0120996 | A | 29-03-2001 | AU 3884401 A | 24-04-2001 |
| WO 2004039159 | A | 13-05-2004 | AU 2003284373 A1 | 25-05-2004 |
| | | | BR 0315808 A | 20-09-2005 |
| | | | EP 1555879 A1 | 27-07-2005 |